

Anti-Infective Agents - Global Market Outlook (2017-2023)

<https://marketpublishers.com/r/AC9302F827EEN.html>

Date: November 2017

Pages: 134

Price: US\$ 4,150.00 (Single User License)

ID: AC9302F827EEN

Abstracts

According to Statistics MRC, the Global Anti-Infective Agents Market is accounted for \$86.7 billion in 2016 and expected to grow at a CAGR of 3.8% to reach \$113.16 billion by 2023. Rising incidences of infectious diseases such as HIV, H1N1, and Ebola virus, awareness amongst the patients, commercialization of pipeline products, Govt collaborating with pharmaceutical companies for the development of new agents, development of new multi-drug resistance against micro-organisms are boosting the market growth. Treatment rates for communicable diseases in developing countries and treatment of Community Acquired Bacterial Pneumonia (CABP) are expected to impart the market growth. Growing resistance of infection to the drug therapies, high price of drugs, competition between generic manufacturers and perilous reimbursement policies will impede market growth.

Based on Product, most of the Antibacterial agents are in pipeline for the modifications of existing antibiotic classes. More innovative products are required against pathogens with no cross- or co-resistance to existing classes. Many of the products in the clinical pipeline are already funded by research grants from public and philanthropic institutions. For instance, Delafloxacin was approved by the US Food and Drug Administration on 21 June 2017.

North America commanded the anti-infective agents market and is followed by Europe. Asia Pacific is the fastest growing market due to improvements in healthcare infrastructure, demand for drugs and ongoing government initiatives for various control programs.

Some of the key players in Global Anti-Infective Agents market are Pfizer Ltd, Ranbaxy Laboratories Ltd, Sun Pharmaceutical Industries Ltd., AstraZeneca Plc, Boehringer

Ingelheim, Bristol-Myers Squibb Co, Abbott Laboratories, Bayer Healthcare AG, Cipla Ltd, GlaxoSmithKline Pharmaceuticals Ltd, Merck & Co., Inc, Novartis AG, Glenmark Pharmaceuticals Ltd, Lupin Ltd, Panacea Biotech Ltd and Claris Life Sciences Ltd.

Products Covered:

Antifungal agents

Azoles

Polyenes

Allylamines

Macrolides derivatives

Cresemba

Echinocandins

Antiviral agents

Non-structural protein 5A (NS5A) inhibitors

Non-nucleoside reverse transcriptase inhibitors (NNRTIs)

Protease Inhibitors

Transcriptase Inhibitors

Neuraminidase inhibitors

Integrase strand transfer inhibitor

Chemokine receptor antagonist

DNA Polymerase Inhibitors

Nucleoside Analogs

Antituberculosis agents

Nicotinic acid derivatives

Rifamycin derivatives

Streptomyces derivatives

Aminosalicylates

Diarylquinolines

Hydrazide derivatives

Antitreponemal agents

Vaccines

DNA & Recombinant vector Vaccines

Toxoid vaccines

Live/attenuated Vaccines

Inactivated Vaccines

Antibacterial agents

Clindamycin

Sulfonamides

Tetracyclines

Vancomycin

Cephalosporins

Carbapenems

Fluoroquinolones

Penicillins

Macrolides

Regions Covered:

North America

US

Canada

Mexico

Europe

Germany

UK

Italy

France

Spain

Rest of Europe

Asia Pacific

Japan

China

India

Australia

New Zealand

South Korea

Rest of Asia Pacific

South America

Argentina

Brazil

Chile

Rest of South America

Middle East & Africa

Saudi Arabia

UAE

Qatar

South Africa

Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country level segments

Market share analysis of the top industry players

Strategic recommendations for the new entrants

Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets

Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)

Strategic recommendations in key business segments based on the market estimations

Competitive landscaping mapping the key common trends

Company profiling with detailed strategies, financials, and recent developments

Supply chain trends mapping the latest technological advancements

Contents

1 EXECUTIVE SUMMARY

2 PREFACE

- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
 - 2.4.1 Data Mining
 - 2.4.2 Data Analysis
 - 2.4.3 Data Validation
 - 2.4.4 Research Approach
- 2.5 Research Sources
 - 2.5.1 Primary Research Sources
 - 2.5.2 Secondary Research Sources
 - 2.5.3 Assumptions

3 MARKET TREND ANALYSIS

- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 Product Analysis
- 3.7 Emerging Markets
- 3.8 Futuristic Market Scenario

4 PORTERS FIVE FORCE ANALYSIS

- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry

5 ANTI-INFECTIVE AGENTS MARKET, BY PRODUCT

5.1 Introduction

5.2 Antifungal agents

5.2.1 Azoles

5.2.1.1 Posaconazole

5.2.1.2 Clotrimazole

5.2.1.3 Fluconazole

5.2.1.4 Itraconazole

5.2.1.5 Ketoconazole

5.2.1.6 Voriconazole

5.2.2 Polyenes

5.2.3 Allylamines

5.2.4 Macrolides derivatives

5.2.5 Cresemba

5.2.6 Echinocandins

5.3 Antiviral agents

5.3.1 Non-structural protein 5A (NS5A) inhibitors

5.3.2 Non-nucleoside reverse transcriptase inhibitors (NNRTIs)

5.3.3 Protease Inhibitors

5.3.4 Transcriptase Inhibitors

5.3.5 Neuraminidase inhibitors

5.3.6 Integrase strand transfer inhibitor

5.3.7 Chemokine receptor antagonist

5.3.8 DNA Polymerase Inhibitors

5.3.9 Nucleoside Analogs

5.3.9.1 Purine Nucleosides

5.3.9.2 Pyrimidine Nucleosides

5.4 Antituberculosis agents

5.4.1 Nicotinic acid derivatives

5.4.2 Rifamycin derivatives

5.4.3 Streptomyces derivatives

5.4.4 Aminosalicylates

5.4.5 Diarylquinolines

5.4.6 Hydrazide derivatives

5.5 Antitreponemal agents

5.6 Vaccines

5.6.1 DNA & Recombinant vector Vaccines

5.6.2 Toxoid vaccines

5.6.3 Live/attenuated Vaccines

5.6.4 Inactivated Vaccines

5.7 Antibacterial agents

5.7.1 Clindamycin

5.7.1.1 B-Lactam Antibiotics

5.7.1.2 Oxazolidinones

5.7.1.3 Aminoglycosides

5.7.1.4 Quinolones

5.7.2 Sulfonamides

5.7.3 Tetracyclines

5.7.4 Vancomycin

5.7.5 Cephalosporins

5.7.6 Carbapenems

5.7.7 Fluoroquinolones

5.7.8 Penicillins

5.7.8.1 Penicillinase resistant penicillins

5.7.8.2 Natural penicillins

5.7.8.3 Beta-lactamase inhibitors

5.7.8.4 Antipseudomonal penicillins

5.7.8.5 Aminopenicillins

5.7.9 Macrolides

5.7.9.1 Erythromycin

5.7.9.2 Sulfisoxazole

5.7.9.3 Azithromycin

5.7.9.4 Clarithromycin XL

6 ANTI-INFECTIVE AGENTS MARKET, BY GEOGRAPHY

6.1 Introduction

6.2 North America

6.2.1 US

6.2.2 Canada

6.2.3 Mexico

6.3 Europe

6.3.1 Germany

6.3.2 UK

6.3.3 Italy

6.3.4 France

6.3.5 Spain

6.3.6 Rest of Europe

6.4 Asia Pacific

6.4.1 Japan

6.4.2 China

6.4.3 India

6.4.4 Australia

6.4.5 New Zealand

6.4.6 South Korea

6.4.7 Rest of Asia Pacific

6.5 South America

6.5.1 Argentina

6.5.2 Brazil

6.5.3 Chile

6.5.4 Rest of South America

6.6 Middle East & Africa

6.6.1 Saudi Arabia

6.6.2 UAE

6.6.3 Qatar

6.6.4 South Africa

6.6.5 Rest of Middle East & Africa

7 KEY PLAYER ACTIVITIES

7.1 Acquisitions & Mergers

7.2 Agreements, Partnerships, Collaborations and Joint Ventures

7.3 Product Launch & Expansions

7.4 Other Activities

8 LEADING COMPANIES

8.1 Pfizer Ltd

8.2 Ranbaxy Laboratories Ltd

8.3 Sun Pharmaceutical Industries Ltd.

8.4 AstraZeneca Plc

8.5 Boehringer Ingelheim

8.6 Bristol-Myers Squibb Co

8.7 Abbott Laboratories

8.8 Bayer Healthcare AG

8.9 Cipla Ltd

8.10 GlaxoSmithKline Pharmaceuticals Ltd

- 8.11 Merck & Co., Inc
- 8.12 Novartis AG
- 8.13 Glenmark Pharmaceuticals Ltd
- 8.14 Lupin Ltd
- 8.15 Panacea Biotech Ltd
- 8.16 Claris Life Sciences Ltd

List Of Tables

LIST OF TABLES

Table 1 Global Anti-Infective Agents Market Outlook, By Region (2014-2023) (\$MN)

Table 2 Global Anti-Infective Agents Market Outlook, By Product (2014-2023) (\$MN)

Table 3 Global Anti-Infective Agents Market Outlook, By Antifungal agents (2014-2023) (\$MN)

Table 4 Global Anti-Infective Agents Market Outlook, By Azoles (2014-2023) (\$MN)

Table 5 Global Anti-Infective Agents Market Outlook, By Polyenes (2014-2023) (\$MN)

Table 6 Global Anti-Infective Agents Market Outlook, By Allylamines (2014-2023) (\$MN)

Table 7 Global Anti-Infective Agents Market Outlook, By Macrolides derivatives (2014-2023) (\$MN)

Table 8 Global Anti-Infective Agents Market Outlook, By Cresemba (2014-2023) (\$MN)

Table 9 Global Anti-Infective Agents Market Outlook, By Echinocandins (2014-2023) (\$MN)

Table 10 Global Anti-Infective Agents Market Outlook, By Antiviral agents (2014-2023) (\$MN)

Table 11 Global Anti-Infective Agents Market Outlook, By Non-structural protein 5A (NS5A) inhibitors (2014-2023) (\$MN)

Table 12 Global Anti-Infective Agents Market Outlook, By Non-nucleoside reverse transcriptase inhibitors (NNRTIs) (2014-2023) (\$MN)

Table 13 Global Anti-Infective Agents Market Outlook, By Protease Inhibitors (2014-2023) (\$MN)

Table 14 Global Anti-Infective Agents Market Outlook, By Transcriptase Inhibitors (2014-2023) (\$MN)

Table 15 Global Anti-Infective Agents Market Outlook, By Neuraminidase inhibitors (2014-2023) (\$MN)

Table 16 Global Anti-Infective Agents Market Outlook, By Integrase strand transfer inhibitor (2014-2023) (\$MN)

Table 17 Global Anti-Infective Agents Market Outlook, By Chemokine receptor antagonist (2014-2023) (\$MN)

Table 18 Global Anti-Infective Agents Market Outlook, By DNA Polymerase Inhibitors (2014-2023) (\$MN)

Table 19 Global Anti-Infective Agents Market Outlook, By Nucleoside Analogs (2014-2023) (\$MN)

Table 20 Global Anti-Infective Agents Market Outlook, By Antituberculosis agents (2014-2023) (\$MN)

Table 21 Global Anti-Infective Agents Market Outlook, By Nicotinic acid derivatives

(2014-2023) (\$MN)

Table 22 Global Anti-Infective Agents Market Outlook, By Rifamycin derivatives

(2014-2023) (\$MN)

Table 23 Global Anti-Infective Agents Market Outlook, By Streptomyces derivatives

(2014-2023) (\$MN)

Table 24 Global Anti-Infective Agents Market Outlook, By Aminosalicylates (2014-2023) (\$MN)

Table 25 Global Anti-Infective Agents Market Outlook, By Diarylquinolines (2014-2023) (\$MN)

Table 26 Global Anti-Infective Agents Market Outlook, By Hydrazide derivatives (2014-2023) (\$MN)

Table 27 Global Anti-Infective Agents Market Outlook, By Antitreponemal agents (2014-2023) (\$MN)

Table 28 Global Anti-Infective Agents Market Outlook, By Vaccines (2014-2023) (\$MN)

Table 29 Global Anti-Infective Agents Market Outlook, By DNA & Recombinant vector Vaccines (2014-2023) (\$MN)

Table 30 Global Anti-Infective Agents Market Outlook, By Toxoid vaccines (2014-2023) (\$MN)

Table 31 Global Anti-Infective Agents Market Outlook, By Live/attenuated Vaccines (2014-2023) (\$MN)

Table 32 Global Anti-Infective Agents Market Outlook, By Inactivated Vaccines (2014-2023) (\$MN)

Table 33 Global Anti-Infective Agents Market Outlook, By Antibacterial agents (2014-2023) (\$MN)

Table 34 Global Anti-Infective Agents Market Outlook, By Clindamycin (2014-2023) (\$MN)

Table 35 Global Anti-Infective Agents Market Outlook, By Sulfonamides (2014-2023) (\$MN)

Table 36 Global Anti-Infective Agents Market Outlook, By Tetracyclines (2014-2023) (\$MN)

Table 37 Global Anti-Infective Agents Market Outlook, By Vancomycin (2014-2023) (\$MN)

Table 38 Global Anti-Infective Agents Market Outlook, By Cephalosporins (2014-2023) (\$MN)

Table 39 Global Anti-Infective Agents Market Outlook, By Carbapenems (2014-2023) (\$MN)

Table 40 Global Anti-Infective Agents Market Outlook, By Fluoroquinolones (2014-2023) (\$MN)

Table 41 Global Anti-Infective Agents Market Outlook, By Penicillins (2014-2023) (\$MN)

Table 42 Global Anti-Infective Agents Market Outlook, By Penicillinase resistant penicillins (2014-2023) (\$MN)

Table 43 Global Anti-Infective Agents Market Outlook, By Natural penicillins (2014-2023) (\$MN)

Table 44 Global Anti-Infective Agents Market Outlook, By Beta-lactamase inhibitors (2014-2023) (\$MN)

Table 45 Global Anti-Infective Agents Market Outlook, By Antipseudomonal penicillins (2014-2023) (\$MN)

Table 46 Global Anti-Infective Agents Market Outlook, By Aminopenicillins (2014-2023) (\$MN)

Table 47 Global Anti-Infective Agents Market Outlook, By Macrolides (2014-2023) (\$MN)

Table 48 Global Anti-Infective Agents Market Outlook, By Erythromycin (2014-2023) (\$MN)

Table 49 Global Anti-Infective Agents Market Outlook, By Sulfisoxazole (2014-2023) (\$MN)

Table 50 Global Anti-Infective Agents Market Outlook, By Azithromycin (2014-2023) (\$MN)

Table 51 Global Anti-Infective Agents Market Outlook, By Clarithromycin XL (2014-2023) (\$MN)

Note: North America, Europe, Asia Pacific, South America, Middle East and Africa are represented in above manner.

I would like to order

Product name: Anti-Infective Agents - Global Market Outlook (2017-2023)

Product link: <https://marketpublishers.com/r/AC9302F827EEN.html>

Price: US\$ 4,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AC9302F827EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970